unc-105 Antibody

UNC-105: Functional Role and Mutational Analysis

UNC-105 is a nematode degenerin implicated in mechanosensation and muscle function. Specific mutations in unc-105 cause hypercontraction in muscle cells and neuronal degeneration due to constitutive ion channel activity . Key features include:

• Ion Channel Properties:

  • Permeable to small monovalent cations (e.g., Na⁺, K⁺).

  • Voltage-dependent block by Ca²⁺ and Mg²⁺.

  • Amiloride induces voltage-dependent block, suggesting a binding site 65% into the electric field .

• Pathogenic Mutations:

  • Mutations disrupt channel gating, leading to cell death characterized by membranous whorls and vacuolation .

Antibodies with Analogous Naming Conventions

While no "unc-105 Antibody" is described in the provided literature, other antibodies with similar nomenclature are documented:

C105 (SARS-CoV-2 Neutralizing Antibody)

• Target: SARS-CoV-2 spike protein receptor-binding domain (RBD) .

• Neutralization:

  • IC₅₀ (half-maximal inhibitory concentration): 26.1 ng/mL (human assay) .

  • Binds the RBD-ACE2 interface, preventing viral entry .

105AD7 (Anti-Idiotypic Antibody)

• Target: Mimics a colorectal tumor antigen (gp72) .

• Clinical Use: Induced cellular immune responses in colorectal cancer patients, correlating with improved survival (median 12 vs. 4 months in controls) .

TRC105 (Anti-CD105 Antibody)

• Target: CD105 (endoglin), a TGF-β coreceptor on angiogenic endothelial cells .

• Clinical Trials:

  • Phase I: Tolerated at 10 mg/kg weekly, with stable disease in 47% of solid tumor patients .

  • Phase Ib: Synergy with axitinib in renal cell carcinoma .

Antibody Development and Validation

Antibody specificity is critical for research reproducibility. For example:

• The Histone Antibody Specificity Database (www.histoneantibodies.com) validates antibodies using peptide microarrays to ensure binding accuracy .

• CFTR Antibodies: Epitope-mapped monoclonal antibodies (e.g., 1D9, 5E2) target specific domains of the cystic fibrosis transmembrane conductance regulator .

Key Research Gaps

The absence of direct references to "unc-105 Antibody" in the provided sources highlights potential nomenclature confusion or a focus on UNC-105 as a target rather than an antibody. Future studies could explore:

• Development of antibodies targeting UNC-105 for mechanistic studies in nematode models.

• Comparative analysis of degenerin channel blockers (e.g., amiloride derivatives) for therapeutic applications.